Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 13/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27513987 | 0.81 | PTGS1 (0.69) | PTGS1PTGS2KDM4ETP53 | |
| SCHEMBL4718068 | 0.81 | PTGS2 (0.82) | PTGS1PTGS2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4721193 | 0.80 | PTGS1 (1.00) | PTGS1PTGS2 | |
| SCHEMBL4718168 | 0.79 | PTGS1 (0.83) | PTGS1PTGS2KDM4EUSP2ALDH1A1 | |
| SCHEMBL4721120 | 0.79 | PTGS1 (0.83) | PTGS1PTGS2KDM4EUSP2ALDH1A1 | |
| SCHEMBL4718829 | 0.79 | PTGS1 (1.00) | PTGS1PTGS2KDM4EUSP2ALDH1A1 | |
| SCHEMBL4718650 | 0.78 | PTGS1 (0.81) | PTGS1PTGS2KDM4EUSP2ALDH1A1 | |
| SCHEMBL4722523 | 0.77 | PTGS1 (0.76) | PTGS1PTGS2KDM4EUSP2ALDH1A1 | |
| SCHEMBL6408442 | 0.75 | PTGS1 (0.67) | PTGS1PTGS2KDM4ETP53HPGD | |
| SCHEMBL4721292 | 0.75 | SDHB (0.81) | PTGS1PTGS2KDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | claimed |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | claimed |
| US-20060194824-A1 | Compositions containing pyrimidine derivatives as inhibitors of cox-2 | GLAXO GROUP LIMITED (GB) | 2006-08-31 | — | — | US | claimed |
| EP-1687000-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| EP-1687001-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| CN-1255387-C | Pyrimidine derivatives useful as selective COX-2 inhibitors | GLAXO GROUP LTD (GB) | 2006-05-10 | — | — | CN | claimed |
| EP-1390351-B1 | PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2006-05-03 | — | — | EP | claimed |
| US-7026327-B2 | Pyrimidine derivatives useful as selective COX-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2006-04-11 | — | — | US | claimed |
| EP-1569913-A1 | COMPOSITIONS CONTAINING PYRIMIDINE DERIVATIVES AS INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2005-09-07 | — | — | EP | claimed |
| WO-2005049034-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| WO-2005048999-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | claimed |
| US-20050032821-A1 | Pyrimidine derivatives useful as selective cox-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2005-02-10 | — | — | US | claimed |
| WO-2004048344-A1 | COMPOSITIONS CONTAINING PYRIMIDINE DERIVATIVES AS INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2004-06-10 | — | — | WO | claimed |
| EP-1390351-A1 | PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-02-25 | — | — | EP | claimed |
| WO-2002096885-A1 | PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-12-05 | — | — | WO | claimed |
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| CN-101184735-A | Crystalline form of benzazepinium maleate derivative | GLAXO GROUP LTD (GB) | 2008-05-21 | — | — | CN | disclosed |
| WO-2004048344-A1 | COMPOSITIONS CONTAINING PYRIMIDINE DERIVATIVES AS INHIBITORS OF COX-2 | GLAXO GROUP LIMITED (GB) | 2004-06-10 | — | — | WO | disclosed |
| EP-1390351-A1 | PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002096885-A1 | PYRIMIDINE DERIVATIVES USEFUL AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | TPH2, PTGS2, PTGES2 | PTGS1 13/4885PTGS2 2/4885KDM4E 2042/4885 |
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | CYP3A5, GABRA5, SLC6A13 | PTGS1 3843/4885PTGS2 4144/4885KDM4E 404/4885 |
| US-20060194824-A1 | Compositions containing pyrimidine derivatives as inhibitors of cox-2 | DPYD, PTGS2, TYMP | PTGS1 7/4885PTGS2 2/4885KDM4E 2785/4885 |
| US-20050032821-A1 | Pyrimidine derivatives useful as selective cox-2 inhibitors | HRH2, PTGS2, CYP2J2 | PTGS1 5/4885PTGS2 2/4885KDM4E 2449/4885 |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | PTGES2, PTGER2, PTGDR2 | PTGS1 10/4885PTGS2 5/4885KDM4E 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.